Value through Innovation24 April 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Lilly and Boehringer Ingelheim Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue


Clinical data for investigational SGLT2 inhibitor, empagliflozin*, demonstrates potential for oral treatment in type 2 diabetes

- EX US & UK. Medical Media Only.

Boehringer Ingelheim’s novel project transfer program enables fast track to launch for biopharmaceuticals


Unprecedented progression-free survival benefit with afatinib* associated with clinically meaningful improvements in life-limiting lung cancer symptoms and better quality of life

- For NON-US media only

Join the mission on World Heart Day 2012: call for signatures


Change in the Board of Managing Directors at Boehringer Ingelheim


Boehringer Ingelheim opens European Veterinary Research Center in Hanover


New data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance at EASD Annual Meeting

- EX US & UK Medical Media Only

Recruitment complete for two pivotal Phase III studies of nintedanib* in patients with idiopathic pulmonary fibrosis

- For NON-U.S Health Media Only

CHMP recommends indication for the use of Trajenta® (linagliptin) tablets as add-on therapy to insulin in adults with Type 2 Diabetes in Europe

- For Non-U.S. and Non-UK Media

Boehringer Ingelheim submits first oncology compound, afatinib* for European approval

- For NON-US media only

Boehringer Ingelheim launches beta social game Syrum to promote science and innovation

- For Non-US and Non-Canadian Media Only

Asian populations with atrial fibrillation (AF) benefit from better stroke prevention with Pradaxa® (dabigatran etexilate) compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim implements flexible fully disposable up- and downstream manufacturing for biopharmaceuticals


Boehringer Ingelheim and the ETH Zurich announce diabetes and obesity research collaboration


SPIRIVA®* celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD

- For medical media outside the USA and UK

New data show significant improvements in lung function using combination of tiotropium and olodaterol* in COPD patients

- For Media outside the U.S. and UK

Phase III results: tiotropium* Respimat® significantly reduces exacerbations in asthma patients still symptomatic despite ICS/LABA treatment

- For Media outside the U.S. and UK